A groundbreaking study has revealed that a diet brimming with certain foods could slash the rate of prostate cancer progression by half. Professor of oncology Karim Fizazi said the 20-year research indicates that seeds, fruits, and vegetables may be potent in curbing the advance of this lethal illness.
“These results, even if they need to be confirmed, are encouraging,” Professor Fizazi said, highlighting the additional benefits of such a diet in warding off cardiovascular diseases and diabetes.
The extensive research tracked over 2,000 patients for two decades, uncovering that those indulging in a diet dense with seeds, fruits, and veggies saw their cancer progress at a significantly slower pace. Professor Fizazi enthused: “These results, even if they need to be confirmed, are encouraging. Moreover, numerous studies have already proven that such a diet, rich in antioxidants and with anti-inflammatory action, has a protective effect on the onset of cardiovascular diseases and diabetes.”
Professor Fizazi also recommended that individuals over 60 should consider adopting a whole-foods diet, which could not only fend off chronic ailments like strokes and heart attacks but might also decelerate any existing prostate cancer.
In tandem with the dietary insights, Professor Fizazi highlighted the emergence of a revolutionary urine test that outperforms the traditional Prostate Specific Antigen blood test in early detection and assessment of prostate cancer’s aggressiveness. Speaking to FranceInfo, he said: “This test has the advantage of being much more precise than the Prostate Specific Antigen blood test,” reports Wales Online.
According to him, the new test can detect prostate cancer in its nascent stages, even pinpointing less aggressive forms, thereby guiding the urgency of subsequent examinations and treatments.
The new diagnostic tool could accurately establish the severity or aggression level of prostate cancer, potentially enabling patients to bypass intrusive investigations and treatments. A urine test may offer an alternative to invasive biopsy surgery once it is established.
Professor Fizazi stated: “Even if this test seems very promising, it requires validation on a larger scale before one day being available in our laboratories.”
